Patent Grant
9114238
This invention relates generally to drug delivery using microneedles or other microprojections.
Arrays of microneedles were proposed as a way of administering drugs through the skin in the 1970s, for example in expired U.S. Pat. No. 3,964,482. Microneedle arrays can facilitate the passage of drugs through or into human skin and other biological membranes in circumstances where ordinary transdermal administration is inadequate. Microneedle arrays can also be used to sample fluids found in the vicinity of a biological membrane such as interstitial fluid, which is then tested for the presence of biomarkers.
In recent years it has become more feasible to manufacture microneedle arrays in a way that makes their widespread use financially feasible. U.S. Pat. No. 6,451,240 discloses some methods of manufacturing microneedle arrays. If the arrays are sufficiently inexpensive, for example, they may be marketed as disposable devices. A disposable device may be preferable to a reusable one in order to avoid the question of the integrity of the device being compromised by previous use and to avoid the potential need of resterilizing the device after each use and maintaining it in controlled storage.
Despite much initial work on fabricating microneedle arrays in silicon or metals, there are significant advantages to polymeric arrays. U.S. Pat. No. 6,451,240 discloses some methods of manufacturing polymeric microneedle arrays. Arrays made primarily of biodegradable polymers have some advantages. U.S. Pat. No. 6,945,952 and U.S. Published Patent Applications Nos. 2002/0082543 and 2005/0197308 have some discussion of microneedle arrays made of biodegradable polymers. A detailed description of the fabrication of a microneedle array made of polyglycolic acid is found in Jung-Hwan Park et al., “Biodegradable polymer microneedles: Fabrication, mechanics, and transdermal drug delivery,” J. of Controlled Release, 104:51-66 (2005).
Despite these efforts, there is still a need to find simpler and better methods for the manufacture of polymeric arrays and in particular arrays made of biodegradable polymers. A particular desideratum is a method which works at a relatively low temperature so that temperature sensitive actives may be delivered by means of such arrays.
In an aspect of the invention, an array of microprotrusions is provided comprising an approximately planar base and a plurality of microprotrusions, wherein the array comprises a plurality of layers arranged roughly parallel to the plane of the base, at least two of the plurality of layers comprise different polymers, a first layer of the plurality of layers is contained in the microprojections, and optionally at least one layer of the plurality of layers comprises an active ingredient.
In a further aspect of the invention, an array of microprotrusions is formed by (a) providing a mold with cavities corresponding to the negative of the microprotrusions, (b) casting a solution comprising a biocompatible material and a solvent atop the mold, (c) removing the solvent, (d) demolding the resulting array from the mold, and (e) taking at least one measure to avoid the formation or adverse effects of bubbles.
Before describing the present invention in detail, it is to be understood that this invention is not limited to specific solvents, materials, or device structures, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include both singular and plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an active ingredient” includes a plurality of active ingredients as well as a single active ingredient, reference to “a temperature” includes a plurality of temperatures as well as single temperature, and the like.
Where a range of values is provided, it is intended that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. For example, if a range of 1 μm to 8 μm is stated, it is intended that 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, and 7 μm are also disclosed, as well as the range of values greater than or equal to 1 μm and the range of values less than or equal to 8 μm.
In this application reference is often made for convenience to “skin” as the biological membrane through which the active is administered. It will be understood by persons of skill in the art that in most or all instances the same inventive principles apply to administration through other biological membranes such as those which line the interior of the mouth, gastro-intestinal tract, blood-brain barrier, or other body tissues or organs or biological membranes which are exposed or accessible during surgery or during procedures such as laparoscopy or endoscopy.
In this application reference is also made to “microneedles” as the type of microprotrusion or microprojection which is being employed. It will be understood by persons of skill in the art that in many cases the same inventive principles apply to the use of other microprotrusions or microprojections to penetrate skin or other biological membranes. Other microprotrusions or microprojections may include, for example, microblades as described in U.S. Pat. No. 6,219,574 and Canadian patent application no. 2,226,718, and edged microneedles as described in U.S. Pat. No. 6,652,478.
In general it is preferred that the microprojections have a height of at least about 100 μm, at least about 150 μm, at least about 200 μm, at least about 250 μm, or at least about 300 μm. In general it is also preferred that the microprojections have a height of no more than about 1 mm, no more than about 500 μm, no more than about 300 μm, or in some cases no more than about 200 μm or 150 μm. The microprojections may have an aspect ratio of at least 3:1 (height to diameter at base), at least about 2:1, or at least about 1:1. A particularly preferred shape for the microprojections is a cone with a polygonal bottom, for example hexagonal or rhombus-shaped. Other possible microprojection shapes are shown, for example, in U.S. Published Patent App. 2004/0087992. Microprojections may in some cases have a shape which becomes thicker towards the base, for example microprojections which have roughly the appearance of a funnel, or more generally where the diameter of the microprojection grows faster than linearly with distance to the microprojection's distal end. Such a shape may, for example, facilitate demolding.
Where microprojections are thicker towards the base, a portion of the microprojection adjacent to the base, which we may call “foundation,” may be designed not to penetrate the skin.
The number of microprotrusions in the array is preferably at least about 100, at least about 500, at least about 1000, at least about 1400, at least about 1600, or at least about 2000. The area density of microprotrusions, given their small size, may not be particularly high, but for example the number of microprotrusions per cm2 may be at least about 50, at least about 250, at least about 500, at least about 750, at least about 1000, or at least about 1500.
In an aspect of the invention, an array of microprotrusions is formed by (a) providing a mold with cavities corresponding to the negative of the microprotrusions, (b) casting atop the mold a solution comprising a biocompatible material and a solvent, (c) removing the solvent, (d) demolding the resulting array from the mold. The solution preferably contains an active ingredient.
The molds used to form the microneedles in methods of the invention can be made using a variety of methods and materials. In contrast to other methods of making microneedle arrays, for the methods of the invention no particularly high degree of heat resistance is necessarily required of the mold.
The mold may, for example, conveniently comprise a ceramic material. Alternatively, for example, the mold may comprise a silicone rubber or a polyurethane. The mold may alternatively comprise a wax. A particular silicone rubber system which may be used is the Sylgard® system from Dow Corning (Midland, Mich.), for example Sylgard 184. Nusil MED 6215 is an alternative system available from NuSil Technology (Carpinteria, Calif.). The mold may conveniently be made of or comprise a porous material.
There are a number of ways of making the molds. The molds can be made, for example, by casting the liquid mold material over a master microneedle array and allowing the material to dry and harden. In some cases, curing of the material may take place during the drying process. For some materials curing agents may be added. Silicone rubbers and polyurethane are two types of materials that can be used to make molds in this way.
The molds can be made by heating the mold material until it melts. The liquid is then cast over the master microneedle array and allow the material to cool and harden. Waxes and thermoplastics are two classes of materials that can be used to make molds in this way.
The molds can be made by pressing the master microneedle array into the mold material. For this manufacturing technique, the mold material is preferably much softer than the microneedle array. The mold material can be heated to soften it. Waxes and thermoplastics are two types of materials that can be used to make molds in this way.
The molds can be made by plating metal (such as nickel, copper or gold) onto a master microneedle array.
The molds can be made by machining the cavities into the mold material. Electrostatic discharge machining (EDM) can be used to make cavities in metals. Reactive ion etching (RIE) can be used to create the cavities, for example, in silicon and other semiconductors.
The step of casting may be performed by a number of methods known to those of skill in the art. Example 1 describes briefly a way of performing the step of casting. Goals of casting include roughly uniform coverage of the surface of the mold on which the microneedle array is expected to be formed.
The solution which is cast preferably comprises one or more polymers in a solvent and an active ingredient. The polymers should be biocompatible. The polymers are preferably biodegradable. By this term we mean that a polymer will degrade under expected conditions of in vivo use (e.g., insertion into skin), irrespective of the mechanism of biodegradation. Exemplary mechanisms of biodegradation include disintegration, dispersion, dissolution, erosion, hydrolysis, and enzymatic degradation.
For example, suitable biocompatible, biodegradable, or bioerodible polymers include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid)s (PLGAs), polyanhydrides, polyorthoesters, polyetheresters, polycaprolactones (PCL), polyesteramides, poly(butyric acid), poly(valeric acid), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), polyethylene glycol (PEG), block copolymers of PEG-PLA, PEG-PLA-PEG, PLA-PEG-PLA, PEG-PLGA, PEG-PLGA-PEG, PLGA-PEG-PLGA, PEG-PCL, PEG-PCL-PEG, PCL-PEG-PCL, copolymers of ethylene glycol-propylene glycol-ethylene glycol (PEG-PPG-PEG, trade name of Pluronic® or Poloxamer®), dextran, hetastarch, tetrastarch, pentastarch, hydroxyethyl starches, cellulose, hydroxypropyl cellulose (HPC), sodium carboxymethyl cellulose (Na CMC), thermosensitive HPMC (hydroxypropyl methyl cellulose), polyphosphazene, hydroxyethyl cellulose (HEC), other polysaccharides, polyalcohols, gelatin, alginate, chitosan, hyaluronic acid and its derivatives, collagen and its derivatives, polyurethanes, and copolymers and blends of these polymers. A preferred hydroxyethyl starch may have a degree of substitution of in the range of 0-0.9.
The polymers used in the invention may have a variety of molecular weights. The polymers may, for example, have molecular weights of at least about 5 kD, at least about 10 kD, at least about 20 kD, at least about 22 kD, at least about 30 kD, at least about 50 kD, or at least about 100 kD.
Preferred solvents for casting include water, alcohols (for example, C2 to C8 alcohols such as propanol and butanol), and alcohol esters, or mixtures of these. Other possible non-aqueous solvents include esters, ethers, ketones, nitrites, lactones, amides, hydrocarbons and their derivatives as well as mixtures thereof.
In the step of casting the solution on the mold, it is commonly desired to avoid the presence of bubbles of air between the solution and the mold when it is cast. A number of techniques may be employed within the methods of the invention for avoiding these bubbles.
The mold itself, or portions of it, may be subject to surface treatments which make it easier for the solution to wet the mold surface. For example, the mold surface can be coated with a surfactant such as Jet Dry, polysorbate, docusate sodium salt, benzethonium chloride, alkyltrimethylammonium bromide or hexadecyltrimethylammonium bromide (CTAB). Wettability of silicone mold surfaces may be improved by covering them with a solution of hydroxypropylcellulose (HPC) in organic solvent.
The mold surface can be coated with a salt such as calcium carbonate. Calcium carbonate can conveniently be formed in situ from calcium bicarbonate. The mold surface is coated by covering it with a solution containing equivalent quantities of calcium chloride and sodium bicarbonate to form calcium bicarbonate solution in situ. Ultrasonic energy is then applied to precipitate the calcium carbonate salt which is formed as calcium bicarbonate decomposition product under these conditions.
The wettability of the mold surface can also be improved by radiofrequency (RF) or plasma treatment. Alternatively, it is possible to attach to the surface appropriate small molecules, for example in a reaction which is triggered by ultraviolet light. Exemplary small molecules are vinyl monomers comprising carboxyl, primary or secondary or tertiary amine and/or hydroxyl groups, for example acrylic acid, methacrylic acid, allyl amine, or hydroxyethyl methylacrylate (HEMA).
Surface treatments suitable for inducing hydrophilicity are described also in U.S. Published Patent Application No. 20060097361.
A wetting agent, for example Dow Corning Q2-5211, can be added to the mold itself as it is being formed. Q2-5211 is described by Dow Corning as a low molecular weight nonionic silicone polyether surfactant. Being mixed in with the mold as it is formed, the wetting agent becomes part of the mold.
A surfactant such as alkyltrimethylammonium bromide (Cetrimide), hexadecyltrimethylammonium bromide (CTAB), benzethonium chloride, docusate sodium salt, a SPAN-type surfactant, polysorbate (Tween), sodium dodecyl sulfate (SDS), benzalkonium chloride, or glyceryl oleate can be added to the solution.
An anti-foaming agent can be added to the solution. Exemplary antifoaming agents include Dow Corning's FG-10 antifoam Emulsion, Antifoam C Emulsion, 190 fluid, and 193C fluid.
The cavities can be filled with a wetting liquid that easily flows into the cavities and will be absorbed by the mold. The wetting liquid could be ethyl acetate or silicone fluid when the mold is made of silicone rubber. The drug solution is cast over the wetting liquid and is drawn into the cavities as the wetting liquid is absorbed.
The drug solution can be cast onto the mold while a vacuum is applied over the cavities. A low-pressure bubble covered with a liquid film of drug solution can form in the cavities. When the vacuum is removed, the higher pressure over the liquid film will shrink the bubble in the cavity and push the drug solution in behind it.
Alternatively, the mold may be designed to possess a porosity sufficient to allow air to escape from bubbles that may be found between the solution and the mold, but not sufficient for the solution itself to enter the mold's pores.
A further technique which may be employed to avoid air bubbles is to place the mold under compression prior to casting. The compression may be, for example, from two opposite sides. The compression will tend to reduce the volume of the cavities into which the solution must enter. The solution is then cast on the compressed mold. The compression is then released. Upon releasing the compression, the solution is drawn into the cavities as they expand to their normal volume. This process can be performed across the entire mold simultaneously or can be performed on sections of the mold.
The step of casting may alternatively be carried out under an atmosphere which passes more readily through the solution than air would, for example carbon dioxide or another gas whose solubility is greater than that of nitrogen or oxygen, the major constituents of air.
If a bubble is not prevented from forming in a cavity, several methods can be used to remove the bubble. For example, the bubble may be dislodged by vibrating the mold with the drug solution on it.
Pressurization of the cast solution and mold may help eliminate bubbles. In general, the gas in a bubble is expected to diffuse into the liquid over a period of time. When this happens, drug solution is expected to flow into the cavity due to gravitational pull and hydrostatic pressure. The filling and diffusion processes can be accelerated by pressurization. Drying of the liquid is preferably slowed during this period so the liquid can flow into the cavity as the gas from the bubble diffuses into the liquid. Pressurization can be accomplished by placing the mold with the drug solution on it into a pressure vessel. Pressurization may involve a pressure of at least about 3 psi, about 5 psi, about 10 psi, about 14.7 psi, or about 20 psi above atmospheric.
The Epstein-Plesset equation for the time to the dissolution of a bubble in a liquid gives at least a qualitative understanding of the bubble dissolution taking place when the mold and cast solution are pressurized. However, generally the bubbles in mold cavities will have roughly a conical shape and the bubbles hypothesized by Epstein and Plesset were spherical.
Thus, for example, an exemplary method of casting dispenses the solution on the mold over the cavities. A vacuum is applied, causing air trapped in cavities to expand. The air bubbles flow towards the surface of the solution, which in turn flows down into the cavities. When the pressure is returned to atmospheric, the expanded air left in the cavities compresses down.
Another exemplary method of casting dispenses the solution on the mold over the cavities. An overpressure is applied, for example about 0.5 atmospheres, about 1 atmosphere, or about 1.5 atmospheres, causing air bubbles trapped in cavities to contract. The higher pressure causes the air trapped in the bubbles to dissolve into the liquid and causes the bubbles eventually to disappear. After a suitable time the overpressure can be removed. In order to prevent the formulation from drying during this process, the environment surrounding the mold can be humidified.
A vacuum can be applied after the drug solution is cast over the cavities to make the bubbles expand which increases the force pushing them up through the drug solution. The bubbles then rise to the surface of the liquid and the liquid fills the cavities. Drying of the liquid is preferably slowed during this period so the liquid can flow into the cavity as the bubble rises.
It is possible to combine many of the bubble prevention or elimination methods which are listed above.
During the process of solvent removal, the volume of the cast solution will naturally diminish. With an appropriate choice of solvents, it is possible for the distal ends of the microprojections—those furthest from the base—to become finer as a result of solvent removal. Fineness in these tips may be favorable, all else being equal, for easier penetration of the skin, and may thus be desired. A tip diameter of less than about 10 μm, 5 μm or 2 μm is desirable. A tip diameter of less than about 1.5 μm is desirable, as is a tip diameter of less than about 1 μm.
The solvent removal may be accomplished, for example, by heat, vacuum, or convection. The solvent removal may be assisted by covering the cast solution with an absorbent material.
Particularly where the active ingredient is macromolecular, it is desirable to avoid extensive use of heat in the solvent removal step because of the possibility of irreversible denaturation of the active. For example, it is preferable if no temperature above about 100° C. is used (except perhaps for a brief period), more preferably no temperature above about 90° C., and more preferably no temperature above about 85° C. or 80° C. is employed. More preferably, no temperature above about 50° C., 40° C. or 37° C. is employed.
Cast microprojection arrays may be removed from the mold by using a de-mold tool which has a rolling angle of about 1-90 degrees from the plane. A double-sided adhesive is placed on the back of microprojection array with one side for adhering to the array and the other side for adhering to the de-mold tool. The array is removed from the mold by gently rolling the de-mold tool over the adhesive on the back of the array with a slight the rolling angle, such as about 1-90 degrees, preferred about 5-75 degrees, more preferred about 10-45 degrees. The microprojection array is then gently peeled off from the de-mold tool.
In an aspect of the invention, an array of microprotrusions is provided comprising an approximately planar base and a plurality of microprotrusions, wherein the array comprises a plurality of layers arranged roughly parallel to the plane of the base, at least two of the plurality of layers comprise different polymers, and optionally at least one layer of the plurality of layers comprises an active ingredient.
Arrays of the invention may be designed, for example, such that at least one layer of the array adheres to human skin.
There are a number of reasons why arrays with multiple layers may be desirable. For example, it is often desirable that, compared to the whole volume of the microprojection array, the microprojections themselves have a higher concentration of active ingredient. This is so, for example, because the microprojections can be expected in many cases to dissolve more rapidly, being more hydrated than the base of the array. Furthermore, in some protocols for array application, the array may be left in for a short period of time during which essentially only the microprojections can dissolve to a substantial extent. The desirability of placing a higher concentration of active in the projections themselves is particularly acute when the active is costly. A way to achieving a higher concentration of active in the projections themselves is to have a first layer which includes the microprojections or a substantial proportion of the microprojections, and a second layer which includes the base or a substantial proportion of the base.
In a further type of microprojection array 80 shown schematically in cross-section in
Example 8 discloses fabrication procedures by which microprojection arrays of the type of array 80 may be made. The materials for layer 82 need to be chosen so that the enclosure of the deposits 84 can be achieved. Exemplary polymers suitable for use in layer 82 include poly(lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), poly(caprolactone), polyanhydrides, polyamines, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyphosphoesters, polyorthocarbonates, polyphosphazenes, poly(malic acid), poly(amino acids), hydroxycellulose, polyphosphoesters, polysaccharides, chitin, and copolymers, terpolymers and mixtures of these.
A further type of three-layer microprojection array 100 is shown schematically in cross-section in
While
In a method of the invention, the solution comprising the active is cast so that it fills the cavities of a mold partially or fills no more than the cavities. This solution is dried. A further solution with a lower or zero concentration of active, constituting a second layer, is then cast over the solution comprising the active. The polymers used in the first layer are preferably not soluble in the solvent used for the second layer. The second layer preferably uses a different polymer or polymers from the ones used in the first layer. This procedure may produce an array which array has two layers and in which the microprojections are enriched in active. In such an array, the active would not be expected to substantially diffuse into the first layer.
The second layer may comprise, for example, cellulose acetate butyrate, cellulose acetate, cellulose acetate propionate, ethyl cellulose, nitrocellulose, hydroxypropyl methyl cellulose phthalate, polystyrene, polyacrylates (such as acrylate/octylacrylamide copolymers, Dermacryl 97), polymethacrylates (such as Eudragits E, RL, RS, L100, S100, L100-55), or poly(hydroxyl alkanoates). Preferably the second layer may comprise biocompatible, biodegradable polymer(s) such as PLA, PGA, PLGA, polycaprolactone and copolymers thereof. Preferably where the first layer is cast in an aqueous solvent, the second layer is cast in an organic solvent. Preferred solvents for the second layer include alcohols, for example isopropyl alcohol and ethanol, and esters, for example ethyl acetate, heptane, or propyl acetate, or other solvents such as acetonitrile, dimethylsulfone (DMSO), N-methylpyrrolidone (NMP), or glycofurol.
In a multi-layer microprojection array, the first layer, instead of being placed into the mold by a method such as bulk casting, may alternatively be transported into each individual mold cavity as an individual droplet. In recent decades systems have been developed for putting down many small drops automatically onto substrates in a regular pattern. Such systems may operate, for example, on a piezoelectric or bubble jet principle. An early application of these capabilities was inkjet printing in which ink was impelled towards a substrate such as a sheet of paper according to a computer-controlled pattern. A variety of other types of liquids, including liquids containing biomolecules, have also been deposited by such techniques. Exemplary patents discussing this type of technology include U.S. Pat. Nos. 6,713,021, 6,521,187, 6,063,339, 5,807,522, and 5,505,777. Commercial products for such applications are available, for example, from BioDot, Inc. (Irvine, Calif.), MicroFab Technologies, Inc. (Plano, Tex.), and Litrex Corporation (Pleasanton, Calif.).
A typical dispensing arrangement (see
In addition to piezoelectric transducers, other ways of impelling the liquid from a dispensing head have been discussed in the literature. For example, a gas may be used, or the movement of a member driven by a magnetic field.
A major consideration favoring the placement of the first layer in the form of droplets into the mold cavity is the potential savings of drug substance that can result if the first layer is the only drug-containing layer. This can be of particular value if the drug substance is expensive.
A consideration in the placement of the first layer in the form of droplets is the variability in the size of the droplets which is placed in each cavity. It is preferred that the droplet volumes have a coefficient of variation of no more than about 25%, no more than about 15%, no more than about 10%, no more than about 5%, or no more than about 2%.
It is also desirable that the droplets arrive fairly precisely into the centers of the mold cavities so that following the process of filling they are located near the bottoms of the cavities. Cavity openings may typically have diameters on the order of approximately 100 μm. It may therefore be desired, for example, that the droplet center lie within a radius of about 15, 25, or 35 μm around the center of the cavity opening. As will be seen by the person of skill in the art, a number of factors go into determining whether this degree of precision can be achieved routinely. For example, the molds should have a dimensional stability which makes this degree of precision achievable. Their alignment relative to the dispensing device should also be controllable to the requisite degree of precision.
Preferably the droplets would displace the air in the mold cavities so air would not be trapped inside the mold cavities under the formulation. Each droplet preferably enters the cavity into which it is transported without splashing or bouncing (i.e., remains in the cavity after being transported into it). In order to achieve this, it may be desirable to control the energy or velocity or momentum of the droplets at the time that they strike the cavity. Additional drops of formulation could be added to the cavities either before or after the formulation that was previously dispensed has dried.
The diameter of the droplets is preferably smaller than the opening of the microneedle cavity in the mold. For example, a typical microneedle may be 200 μm long with a hexagonal base and a 10° draft on each face. The base of this microneedle would then be 71 μm from face to face. The volume of this microneedle is approximately 280 pL. The cavity in the mold to make this microneedle has approximately the same dimensions. A drop of fluid used to fill the cavity is preferably smaller in diameter than the opening of the cavity. To meet this constraint, the drop should consequently be less than 71 μm in diameter. A 71 μm diameter sphere has a volume of 187 pL. Thus, it may be desirable to dispense droplets in the range from about 50 pL to about 100 pL, about 150 pL, about 200 pL, about 250 pL, about 300 pL or about 500 pL, or about 1 nL.
The biodegradability of a microneedle array may be facilitated also by the inclusion of sugars. Exemplary sugars which may be included in a microneedle array include dextrose, fructose, galactose, maltose, maltulose, iso-maltulose, mannose, lactose, lactulose, sucrose, and trehalose. Sugar alcohols, for example lactitol, maltitol, sorbitol, and mannitol, may also be employed. Cyclodextrins can also be used advantageously in microneedle arrays, for example α, β, and γ cyclodextrins, for example hydroxypropyl-β-cyclodextrin and methyl-β-cyclodextrin. Sugars and sugar alcohols may also be helpful in stabilization of certain actives (e.g., proteins) and in modifying the mechanical properties of the microprojections by a plasticizing-like effect.
The biodegradability of a microneedle array may be facilitated by inclusion of water-swellable polymers such as crosslinked PVP, sodium starch glycolate, celluloses, natural and synthetic gums, or alginates.
In a multilayer array, the sugars and other polymers which facilitate biodegradability may be located only in a layer or layers which encompass the microprojections.
The microneedle arrays of the invention are suitable for a wide variety of drug substances. Suitable active agents that may be administered include the broad classes of compounds such as, by way of illustration and not limitation: analeptic agents; analgesic agents; antiarthritic agents; anticancer agents, including antineoplastic drugs; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics, antifungal agents, antiviral agents and bacteriostatic and bactericidal compounds; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; anxiolytics; appetite suppressants; attention deficit disorder and attention deficit hyperactivity disorder drugs; cardiovascular preparations including calcium channel blockers, antianginal agents, central nervous system agents, beta-blockers and antiarrhythmic agents; caustic agents; central nervous system stimulants; cough and cold preparations, including decongestants; cytokines; diuretics; genetic materials; herbal remedies; hormonolytics; hypnotics; hypoglycemic agents; immunosuppressive agents; keratolytic agents; leukotriene inhibitors; mitotic inhibitors; muscle relaxants; narcotic antagonists; nicotine; nutritional agents, such as vitamins, essential amino acids and fatty acids; ophthalmic drugs such as antiglaucoma agents; pain relieving agents such as anesthetic agents; parasympatholytics; peptide drugs; proteolytic enzymes; psychostimulants; respiratory drugs, including antiasthmatic agents; sedatives; steroids, including progestogens, estrogens, corticosteroids, androgens and anabolic agents; smoking cessation agents; sympathomimetics; tissue-healing enhancing agents; tranquilizers; vasodilators including general coronary, peripheral and cerebral; vessicants; and combinations thereof.
In general certain drug substances (e.g., nitroglycerin) will transport readily through skin, without any special formulation requirements. Other drug substances will transport through skin with greater difficulty and, with a practical-sized system for application, only with the assistance of enhancers. Other substances are not suitable for transdermal administration even with available enhancers and thus benefit particularly from the channels which microneedles are able to produce. Such substances include, for example, peptidic or other large molecule substances for which oral administration is also not an option.
Examples of peptides and proteins which may be used with microneedle arrays are oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), prolactin, luteinizing hormone, follicle stimulating hormone, luliberin or luteinizing hormone releasing hormone (LHRH), insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, kyotorphin, taftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor, serum thymic factor, tumor necrosis factor, colony stimulating factors, motilin, bombesin, dinorphin, neurotensin, cerulein, bradykinin, urokinase, kallikrein, substance P analogues and antagonists, angiotensin II, nerve growth factor, blood coagulation factors VII and IX, lysozyme chloride, renin, bradykinin, tyrocidin, gramicidines, growth hormones, melanocyte stimulating hormone, thyroid hormone releasing hormone, thyroid stimulating hormone, parathyroid hormone, pancreozymin, cholecystokinin, human placental lactogen, human chorionic gonadotropin, protein synthesis stimulating peptide, gastric inhibitory peptide, vasoactive intestinal peptide, platelet derived growth factor, growth hormone releasing factor, bone morphogenic protein, and synthetic analogues and modifications and pharmacologically active fragments thereof. Peptidyl drugs also include synthetic analogs of LHRH, e.g., buserelin, deslorelin, fertirelin, goserelin, histrelin, leuprolide (leuprorelin), lutrelin, nafarelin, tryptorelin, and pharmacologically active salts thereof.
Macromolecular active agents suitable for microneedle array administration may also include biomolecules such as antibodies, DNA, RNA, antisense oligonucleotides, ribosomes and enzyme cofactors such as biotin, oligonucleotides, plasmids, and polysaccharides. Oligonucleotides include DNA and RNA, other naturally occurring oligonucleotides, unnatural oligonucleotides, and any combinations and/or fragments thereof. Therapeutic antibodies include Orthoclone OKT3 (muromonab CD3), ReoPro (abciximab), Rituxan (rituximab), Zenapax (daclizumab), Remicade (infliximab), Simulect (basiliximab), Synagis (palivizumab), Herceptin (trastuzumab), Mylotarg (gemtuzumab ozogamicin), CroFab, DigiFab, Campath (alemtuzumab), and Zevalin (ibritumomab tiuxetan).
Macromolecular active agents suitable for microneedle array administration may also include vaccines such as, for example, those approved in the United States for use against anthrax, diphtheria/tetanus/pertussis, hepatitis A, hepatitis B, Haemophilus influenzae type b, human papillomavirus, influenza, Japanese encephalitis, measles/mumps/rubella, meningococcal diseases (e.g., meningococcal polysaccharide vaccine and meningococcal conjugate vaccine), pneumococcal diseases (e.g., pneumococcal polysaccharide vaccine and meningococcal conjugate vaccine), polio, rabies, rotavirus, shingles, smallpox, tetanus/diphtheria, tetanus/diphtheria/pertussis, typhoid, varicella, and yellow fever.
In a further aspect of the invention, it may be desired that the microprojections of the array detach from the array following insertion of the array into skin.
One major advantage of detaching and dissolving microprojections is elimination of sharp disposal requirements. Another advantage of detaching and dissolving microprojections is elimination of needle stick injury. Another advantage of detaching and dissolving microprojections is elimination of misuse, for example needle sharing, since the substrate without microprojections or with microprojections whose tips have been blunted due to biodegradation will not penetrate the skin. Another advantage of detaching and dissolving microprojections is the avoidance of drug misuse because drug enriched tips are dissolved in the skin and no or minimal drug is left in the array.
Detachable microprojections may be accomplished by a number of approaches. A layered approach, for example, may be used in which the array is composed of multiple layers, and a layer comprising the attachment areas of the microprojections to the array is more readily degradable than other layers. For example, the layer comprising the attachment areas of microprojections to array may be one which is more rapidly hydrated than the other layers.
Alternatively, an array made of a homogeneous material may be employed, in which the material is more readily degradable at lower pH's. Arrays made of such a material will tend to degrade more readily near the attachment points because these, being closer to the surface of the skin, are at a lower pH than the distal ends of the microprojections. (The pH of the skin's surface is generally lower than that of the skin further inwards, pH being for example approximately 4.5 on the surface and approximately 6.5 to 7.5 inward.)
Materials whose solubility is dependent on pH can be, for example, insoluble in pure water but dissolve in acidic or basic pH environment. Using such materials or combination of materials the arrays can be made to differentially biodegrade at skin surface (pH approximately 4.5) or inside skin. In the former, the whole array can biodegrade while in latter the microneedle portion of the array will biodegrade while substrate can be removed away.
Materials whose degradability in an aqueous medium is dependent on pH may be made, for example, by utilizing the acrylate copolymers sold by Rohm Pharma under the brand name Eudragit, which are widely used in pharmaceutical formulation. A further example of a material with pH variable solubility is hydroxypropyl cellulose phthalate.
Microneedle arrays made of materials with pH dependent solubility may have additional advantages besides facilitating detachment and differential absorption. For example, they may simplify packaging and handling because of their moisture resistance and rapid hydration and bioadhesion in the buffered acidic or basic environment of the skin.
Microprojection arrays may also be made in which the microprojections have a biodegradability which varies with temperature over the range of expected use conditions, for example in the range of about 25° C. to about 40° C. This may be achieved, for example, by the use of thermosensitive or thermoresponsive polymers. For example, PLGA biodegrades more slowly at higher temperatures. Certain Pluronic polymers are able to solidify with rising temperature. A use for the variation of degradability with temperature is, for example, due to the fact that the microprojections when inserted in skin will tend to have their distal ends at a higher temperature than the portions closer to the base, including the portions (if any) which are not inserted into skin and are thus at a temperature closer to the ambient temperature. The use of a temperature-dependent biodegradability thus offers a further way to tailor the biodegradability along the length of the microprojections.
In a further aspect of the invention, it may be desired that the microneedle array or a layer of the array comprise a polymer or polymer blend with certain bioadhesive characteristics, which within a certain range of moisture will have higher adhesive strength the greater the moisture. It is particularly preferred in a multilayer array that the layer or layers in which the microneedles principally lie possess bioadhesive characteristics.
While usable microneedles may be made of a number of biodegradable polymers as indicated in the patents and patent applications cited in the background section, a polymer that has a bioadhesive character has the advantage that no additional array attachment mechanism, for example an additional adhesive arranged along the exterior perimeter of the microneedle array, may be needed. Use of a bioadhesive polymer may also facilitate detachment of the microneedles or microprojections because they will have a greater adhesion to the interior of the skin where there is greater moisture.
The bioadhesive polymers used in the methods of the invention may, for example, increase in adhesiveness from a moisture content of about 2%, about 5%, or about 10% to some upper limit of moisture content. The upper limit of moisture content beyond which adhesiveness ceases to increase is preferably at least about 20%, more preferably at least about 30%, 40%, 50% or 60% moisture content.
Exemplary polymers with bioadhesive characteristics include suitably plasticized polyvinyl alcohol and polyvinylpyrrolidone. An extensive discussion of a class of bioadhesive polymer blends is found in U.S. Pat. No. 6,576,712 and U.S. Published Patent Applications Nos. 2003/0170308 and 2005/0215727, which are incorporated by reference for their teaching of bioadhesive polymer blends and adhesion testing. Preferable bioadhesive polymers are those which possess hydrogen-bonded crosslinks between strands of the primary polymers. These crosslinks may comprise a comparatively small molecule which forms hydrogen bonds to two primary polymer strands. It is believed that certain sugars may act as a small molecule crosslinker in this manner with particular primary polymers such as polyvinyl alcohol.
The bioadhesive character of a polymer or blend may be determined by testing the bulk material for adhesion (e.g., by a peel test) at different levels of hydration. Alternatively, the bioadhesive character may also be seen if a microneedle array as applied to skin becomes more difficult to remove in minutes or tens of minutes after application, since the array may be assumed to become more hydrated during that period of time.
The bioadhesive nature of polymer may allow the polymer to form a channel or plug in the skin to keep pores open for prolonged period of time for drug diffusion. This is particularly useful if the substrate of the array is used as a drug reservoir, containing the same active ingredient or a different active ingredient from the one contained in the microneedles. The bioadhesive array can be also be used to pretreat the skin and leave bioadhesive microneedles inside the skin. This may be followed by application of a solid or liquid reservoir. Due to the channel formation, drug may freely diffuse through bioadhesive channels created and located in the skin.
A bioadhesive array embedded in skin or in another membrane may also be used as a biosensor. It may respond, for example, to biomarkers, pH, hydration, or temperature by itself. Alternatively, it may facilitate the flow of matter from inside the skin through the bioadhesive channel and onto the base or a reservoir placed in the skin adjacent to the array. For example, if the rate of dissolution of microprojections in skin is correlated with some property of the skin (e.g., pH), that property may be measured by embedding microprojections in skin for a measured period of time and then observing the degree to which they have dissolved.
Because microprojection arrays penetrate human skin, it may be desirable to take steps which tend to eliminate the presence of microorganisms in the array. Such steps include, for example, the use of a formulation with high sugar concentration which will act as an osmotic agent to dehydrate microorganisms in the formulation. An alternative technique is the use of a non-physiological pH (e.g., below pH 6 and above pH 8) to retard growth and destroy microbial viability. The formulation may be made with organic solvents which are then dried in order to dehydrate microorganisms. Apart from the dehydration effect, the use of organic solvents is also inherently bactericidal since they disrupt bacterial cell membranes. In addition, the microprojection arrays may be packaged in a sealed, low oxygen environment to retard aerobic microorganisms and eventually destroy their viability. The arrays may also be packaged in a low moisture environment to dehydrate microorganisms.
A further technique to deal with microorganisms is to include a pharmaceutically acceptable antibacterial agent in the formulation or the packaging. Examples of such agents are benzalkonium chloride, benzyl alcohol, chlorbutanol, meta cresol, esters of hydroxyl benzoic acid, phenol, and thimerosal.
As a further alternative, a surfactant or detergent can be added to the formulation to disrupt the cell membrane of any microorganisms to kill them. A desiccant could be added to the packaging to dehydrate microorganisms and kill them.
Antioxidants may be added to the formulation, for example to protect the active from oxidation. Exemplary antioxidants include methionine, cysteine, D-alpha tocopherol acetate, DL-alpha tocopherol, ascorbyl palmitate, ascorbic acid, butylated hydroxyanisole, butylated hydroxyquinone, butylhydroxyanisole, hydroxycomarin, butylated hydroxytoluene, cephalin, ethyl gallate, propyl gallate, octyl gallate, lauryl gallate, propylhydroxybenzoate, trihydroxybutyrophenone, dimethylphenol, ditertbutylphenol, vitamin E, lecithin, and ethanolamine.
In the evaluation of solvent cast or other microneedle arrays, various figures of merit may be employed. A simple visual figure of merit is the completeness of the array under microscopic examination: are any of the microneedles of an unsuitable shape, for example broken off or with unduly blunt or fine ends? It is desirable that no more than about 20%, no more than about 10%, preferably no more than about 5%, and more preferably no more than about 2% of the microneedles have an unsuitable shape upon demolding.
An alternative figure of merit may be obtained by setting up a consistent test for skin penetration efficiency. An exemplary test requires the placement of the microneedle array upon a test sample of cadaver skin, the insertion of the array with a reproducible or standardized force, and the withdrawal of the array after a period of time. At that time the percentage of openings in the skin sample that are deemed to allow adequate transport of material may be taken as a figure of merit. A material that may be used to test adequacy of transport is India ink. It is desirable that at least about 80%, preferably at least about 90%, and more preferably at least about 95% of the openings in the skin allow adequate transport of material.
A further figure of merit for microneedle arrays is transepidermal water loss (TEWL) after application of the array, which is conveniently expressed in units of mass per unit area and time. TEWL measurement has a number of dermatological applications. Commercially available instruments exist for the measurement of TEWL, for example from Delfin Technologies Ltd., Kuopio, Finland. TEWL is conveniently measured before and after the application of a microneedle array to a human test subject, the ratio of the two measured values being an indication of the degree to which the microneedle array disrupts the barrier function of the skin.
For microneedle arrays it may be desired that the ratio of TEWL's after and before application of the microneedles be at least about 1.5, at least about 2.0, more preferably at least about 2.5.
In practice, it may often be helpful for the microneedles produced by processes of the invention to be applied to the skin by means of some mechanism which helps insure a greater uniformity in the skin penetration efficiency. Such mechanisms may include, for example, the applicators disclosed in U.S. Provisional Patent Application No. 60/881,905, which is incorporated by reference.
It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, the foregoing description is intended to illustrate and not limit the scope of the invention. Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.
All patents, patent applications, and publications mentioned herein are hereby incorporated by reference in their entireties. However, where a patent, patent application, or publication containing express definitions is incorporated by reference, those express definitions should be understood to apply to the incorporated patent, patent application, or publication in which they are found, and not to the remainder of the text of this application, in particular the claims of this application.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to implement the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. and pressure is at or near atmospheric.
The mold to be used to form a microneedle array is cleaned with water or other suitable solvent and dried in an incubator. The mold is then placed in a Petri dish. One dispenses a small amount of formulation, for example, 20 μL, on the mold. The formulation may contain, for example, 25% bovine serum albumin (BSA), 20% polyvinyl alcohol, 27% trehalose, and 28% maltitol in water solvent, such that the formulation has, for example, 20% solids content as applied. The formulation is spread manually over the mold using a transfer pipette with a trimmed tip. The formulation is then vortexed, for example for five seconds, using a commercial vibrating instrument to even out the formulation. The mold with the formulation covering it is placed in a pressure vessel under 1 atm for about 10 minutes. Pressure is then removed. The mold is placed in an incubator at a temperature of 32° C., for about 1 hr. The array may then be demolded, for example using double-sided adhesive tape, and optionally attached to a backing.
Following the drying step of Example 1, an additional layer is cast on the mold using similar procedures. The additional layer may, for example, consist of 75 μL of 20 wt % Eudragit EPO in a 3:1 mixture of ethanol and isopropyl alcohol. The additional layer may be spread out, for example, using a glass slide. The mold is placed in a pressure vessel and pressurized at 1 atm for 2 minutes. The pressure is released and the mold is allowed to dry in the pressure vessel for an additional five minutes, without disturbing. The mold is again dried in the incubator for 1 hr at 32° C., and then demolded.
Microneedle arrays were cast from polyvinyl alcohol (PVA) using bovine serum albumin (BSA) as a model drug, water as a solvent, and proportions of PVA, BSA, and other ingredients as indicated below. The general procedure of Example 1 was followed with some variations. Each array was evaluated by microscopic examination. The details of the arrays and their evaluations are given in the table below.
In this table, percentages are by weight, the mannitol is always
The following table gives the evaluation of a further set of microneedle arrays.
It is seen from the tables above that a wide variety of compositions can result in acceptable microneedle arrays.
A microneedle array with two layers can be prepared by the following steps:
1) Casting a solution comprising an active, polymer, and possibly other components in a mold. The clean mold is placed in a mold holder. One dispenses a small amount of formulation, for example, 75 μL, as a droplet on the mold, placing a cover slip on top of the droplet to help spread the liquid onto the whole surface of the mold. The formulation may contain, for example, 15% human parathyroid hormone 1-34 fragment (hPTH1-34), 65% dextran 70, 20% sorbitol in a histidine buffer solvent, such that the formulation has, for example, 30% solids content as applied. The mold with the formulation covering it is placed in a pressure vessel under ca. 50 psi for about 30 seconds. Pressure is then removed. The excess formulation is wiped with a silicone wiper with the interference between wiper edge and surface of mold about 1-10 mils. The mold is placed in an incubator at a temperature of 32° C., for about half an hour.
2) Casting an additional layer on top of the first layer in the mold. The mold with drug-containing layer cast is removed from the drying oven, any residue of dry formulation left on the base of the mold is removed by tape strip using a 3M 1516 single-sided adhesive. Then about 150 μL of “basement” solution which comprises poly(lactic acid-co-glycolic acid) (PLGA) with L/G ratio of 75/25 in acetonitrile is placed on the mold (atop the first solution). A thin film is cast using a wiper with the clearance between edge of the wipe and the surface of the mold about 10-20 mil. The mold is then placed into a pressure vessel under 10-30 psi with controlled venting for about 5 min. The mold is further dried at room temperature for about 30 min. The array may then be demolded, for example using double-sided adhesive tape, and optionally attached to a polyethylene terephthalate film as backing.
Microneedle arrays were cast from PVA with sucrose as a sugar excipient, or dextran with sorbitol as a sugar excipient, or tetrastarch with sorbitol as a sugar excipient, bovine serum albumin (BSA) as a model drug, and histidine buffer, pH 5-6, as a solvent. The proportions of polymer, sugar and drug are indicated below. The general procedure of Example 4 was followed with some variations. The details of the formulations used to form the arrays are given in the table below.
The following table gives the details of formulations to form microneedle arrays with hPTH(1-34) as the drug substance.
It is seen from the tables above that a wide variety of compositions can be used to form microneedle arrays in accordance with this invention.
Different polymeric solutions can be used for casting the basement layer for the microneedle arrays. The polymer solutions are prepared by dissolving the polymers in a solvent or solvent mixture at room temperature with polymer concentration about 15-30% by weight. The details of composition of certain polymer solutions used for casting the basement of microneedle arrays are summarized in the table below.
In this table the following abbreviations are used: Polyvinylpyrrolidone (PVP); poly(lactic acid-co-glycolic acid) (PLGA) (L/G ratio 75/25, 65/35); poly(lactic acid) (PLA); and isopropyl alcohol (IPA).
A microneedle array with three layers can be prepared in the following steps:
1) Casting a non-drug containing tip layer in the mold. The clean mold is placed in a mold holder. One dispenses a small amount (20 μL) of formulation solution without drug, as a droplet on the mold. The formulation may contain, for example, 70% dextran 70, 30% sorbitol in histidine buffer solvent, such that the formulation has, for example, 30% solids content as applied. The mold with the formulation covering it is placed in a pressure vessel under ca. 50 psi for about 30 seconds. Pressure is then removed. The excess formulation is wiped with a silicone wiper with the interference between wiper edge and surface of mold about 1-10 mils. The mold is placed in an incubator at a temperature of 32° C., for about half an hour.
Casting drug containing layer in the mold. After the step 1) above, one dispenses a small amount of formulation, for example, 75 μL, as a droplet on the mold, place a cover slip on top of the droplet to help spread the liquid onto the whole surface of the mold. The formulation may contain, for example, 15% human parathyroid hormone 1-34 fragment (hPTH(1-34)), 65% dextran 70, 20% sorbitol in histidine buffer solvent, such that the formulation has, for example, 30% solids content as applied (e.g., B12 in Example 5 above). The mold with the formulation covering it is placed in a pressure vessel under ca. 50 psi for about 30 seconds. Pressure is then removed. The excess formulation is wiped with a silicone wiper with the interference between wiper edge and surface of mold about 1-10 mils. The mold is placed in an incubator at a temperature of 32° C., for about half an hour.
3) Casting the basement layer on top of the drug-containing layer in the mold. After step 2) above, then about 150 μL of basement solution which comprises poly(lactic acid-co-glycolic acid) (PLGA) with L/G ratio of 75/25 in acetonitrile is placed on the mold (on top of the drug-containing layer). A thin film is cast using a wiper with the clearance between edge of the wipe and surface of the mold about 10-20 mil. The mold is then placed into a pressure vessel under 10-30 psi with controlled venting for about 5 min. The mold is further dried at room temperature for about 30 min. The array may then be demolded, for example using double-sided adhesive tape, and optionally attached to a polyethylene terephthalate film as backing.
A microneedle array with a rate controlling layer can be prepared in the following steps:
1) Casting a thin film of PLGA at the bottom of each cavity of the mold. The clean mold is placed in a mold holder. One dispenses a small amount (for example 20 μL) of PLGA solution (for example solution C4 of Example 4) as a droplet on the mold. A thin film is cast using a wiper, with the clearance between the edge of the wiper and the surface of the mold being about 1-5 mils. The mold is then placed into a pressure vessel under 10-30 psi for about 30 sec. Pressure is then removed. The excess formulation is wiped with a silicone wiper, with the interference between wiper edge and the mold surface about 1-10 mils. The mold is placed in an incubator at a temperature of 32° C., for about half an hour. Additional steps may be taken to ensure that the thin film of PLGA is spread over the sides of the mold cavity.
2) Casting a drug-containing solution. After the step 1) above, one dispenses a small amount of formulation, for example, 75 μL, as a droplet on the mold, placing a cover slip on top of the droplet to help spread the liquid onto the whole surface of the mold. The formulation may contain, for example, 15% human parathyroid hormone 1-34 fragment (hPTH(1-34)), 65% Dextran 70, 20% sorbitol in histidine buffer solvent, such that the formulation has, for example, 30% solids content as applied (e.g., B12 in Example 5 above). The mold with the formulation covering it is placed in a pressure vessel under ca. 50 psi for about 30 seconds. Pressure is then removed. The excess formulation is wiped with a silicone wiper with the interference between wiper edge and surface of mold about 1-10 mils. The mold is placed in an incubator at a temperature of 32° C., for about half an hour.
3) Casting a thin layer of PLGA on top of the drug-containing layer in the mold. The mold with drug-containing layer cast is removed from the drying oven. Any residues of dry formulation left on the base of the mold are removed by tape strip using a 3M 1516 single-sided adhesive. One then places on the mold, on top of the drug-containing layer, about 10 μL of polymer solution which comprises poly(lactic acid-co-glycolic acid) (PLGA) with L/G ratio of 75/25 in acetonitrile. A thin film is cast using a wiper with the clearance between edge of the wipe and surface of mold about 1-5 mil. The mold is then placed into a pressure vessel under 10-30 psi with controlled venting for about 30 seconds. The mold is further dried at room temperature for about 30 min.
4) Casting a dissolvable layer on top of the thin PLGA layer. After step 3) above, one dispenses a small amount of formulation, for example, 25 μL, as a droplet on the mold and places a cover slip on top of the droplet to help spread the liquid onto the whole surface of the mold. The formulation may contain, for example, 70% Dextran 70, 30% sorbitol in histidine buffer solvent, such that the formulation has, for example, 30% solids content as applied. The mold with the formulation covering it is placed in a pressure vessel under ca. 50 psi for about 30 seconds. Pressure is then removed. The excess formulation is wiped with a silicone wiper with the interference between wiper edge and surface of mold about 1-8 mils. The mold is placed in an incubator at a temperature of 32° C., for about half an hour.
5) Casting a basement layer on top of the dissolvable layer in the mold. After step 4) above, then about 150 μL of basement solution which comprises poly(lactic acid-co-glycolic acid) (PLGA) with L/G ratio of 75/25 in acetonitrile is placed on the mold (on top of the drug-containing solution). A thin film is cast using a wiper, with the clearance between edge of the wipe and surface of mold about 10-20 mil. The mold is then placed into a pressure vessel under 10-30 psi with controlled venting for about 5 min. It is believed that this pressure treatment helps to tailor the depth where the active pharmaceutical ingredient (drug substance) is delivered. The mold is further dried at room temperature for about 30 min. The array may then be demolded, for example using double-sided adhesive tape, and optionally attached to a polyethylene terephthalate film as backing.
A microneedle array for sustained release of drug substance from the array can be prepared in the following steps:
1) Casting a drug-containing layer for sustained release of drug substance. The clean mold is placed in a mold holder. One dispenses a small amount (e.g., 75 μL) of aqueous solution which comprises hPTH(1-34), a polymeric matrix such as polyethylene glycol-co-poly(lactic acid-co-glycolic acid) (PEG-PLGA) copolymer, and excipients such as sucrose or sorbitol. The polymeric matrix is generally amphiphilic in nature. The hydrophobic segment(s) of the polymer can help control the release of drug substance. Examples of such formulations are described in the table below. The liquid formulation is spread manually on the surface of the mold with a glass cover slip. The mold with the formulation covering it is placed in a pressure vessel under ca. 50 psi for about 30 seconds. Pressure is then removed. The excess formulation is wiped with a silicone wiper with the interference between wiper edge and surface of mold about 1-10 mils. The mold is placed in an incubator at room temperature for about half an hour.
The following table gives the details of aqueous solutions to form microneedle arrays, comprising drug substance hPTH, polymeric matrix and excipients.
In the table above, PEG-PLGA denotes a blend of polyethylene glycol and poly(lactic acid-co-glycolic acid).
2) Casting a dissolvable layer on top of the drug-containing layer in the mold. After the step 1) above, one dispenses a small amount of formulation, for example, 25 μL, as a droplet on the mold, place a cover slip on top of the droplet to help spread the liquid onto the whole surface of the mold. The formulation may contain, for example, 70% Dextran 70, 30% sorbitol in histidine buffer solvent, such that the formulation has, for example, 30% solids content as applied. The mold with the formulation covering it is placed in a pressure vessel under ca. 50 psi for about 30 seconds. Pressure is then removed. The excess formulation is wiped with a silicone wiper with the interference between wiper edge and the surface of the mold about 1-8 mils. The mold is placed in an incubator at a temperature of 32° C., for about half an hour.
3) Casting a basement layer on top of the dissolvable layer in the mold. After step 2) above, then about 150 μL of basement solution which comprises poly(lactic acid-co-glycolic acid) (PLGA) with L/G ratio of 75/25 in acetonitrile is placed on the mold (on top of the dissolvable layer) and thin film is cast using a wiper with the clearance between edge of the wipe and surface of mold about 10-20 mil. The mold is then placed into a pressure vessel under 10-30 psi with controlled venting for about 5 min. The mold is further dried at room temperature for about 30 min. The array may then be demolded, for example using double-sided adhesive tape, and optionally attached to a polyethylene terephthalate film as backing.
The meniscus of the drug-containing layer in a solvent cast microneedle array manufacturing process might need to be controlled, for example to improve the consistency of skin penetration or improve efficiency. The meniscus can be controlled during the casting process as described below during the drying process:
The clean mold is placed in a mold holder. One dispenses a small amount (20 μL) of formulation solution without drug, as a droplet on the mold. The formulation may contain, for example, 70% Dextran 70, 30% sorbitol in histidine buffer solvent, such that the formulation has, for example, 30% solids content as applied. The mold with the formulation covering it is placed in a pressure vessel under ca. 50 psi for about 30 seconds. Pressure is then removed. The excess formulation is wiped with a silicone wiper with the interference between wiper edge and surface of mold about 1-10 mils.
One instance of controlling the meniscus of the drug-containing layer is to manage the initial drying of the drug-containing layer as follows: place the mold back in the pressure vessel under ca. 30 psi with controlled venting for 5-10 min, as an initial drying. Pressure is then removed. The mold is further dried in the incubator at a temperature of 32° C., for about 20-30 min.
Another instance of controlling the meniscus of the drug-containing layer is to manage the initial drying of the drug-containing layer as follows: the mold is placed back in a controlled humidity chamber with 50-75% RH for 5-10 min, as an initial drying. Pressure is then removed. The mold is further dried in the incubator at a temperature of 32° C., for about 20-30 min.
Two sets of arrays, E1 and E2, were prepared as described above. Arrays of type E1 were cast from a water solution of 25% by weight bovine serum albumin (BSA), 25% polyvinyl alcohol USP, and 50% trehalose. The water solution contained approximately 16.1% solids content. Arrays of type E2 were (i) cast from a water solution containing approximately 16.3% solids content, which consisted of 25% BSA, 20% polyvinyl alcohol USP, 27% trehalose, and 28% maltitol, producing a layer comprising the microneedles and a portion of the base, and then (ii) cast from 20 wt % Eudragit EPO in 3:1 ethanol:isopropyl alcohol, producing a second layer comprising a portion of the base. Both types of arrays had 200 μm high microneedles with a 400 μm spacing between microneedles. The arrays were 10 mm in diameter. Three arrays of each type were tested.
Skin penetration efficiency was tested using cadaver skin. The donor was a 77 year old white female. The skin was mounted on a foam-cork base and blotted on the stratum corneum side to remove excess moisture and to check for holes.
The microneedle arrays were placed needle-side down directly on skin, the arrays being in contact with skin for less than fifteen seconds. A portable spring-loaded impactor with a 10 mm tip was used to drive the microneedles into skin by impact loading. The impactor was used to hold arrays in skin for one minute. The arrays were then pulled out of the skin. A certain effort was required to pry the arrays out of the skin, confirming that the arrays possessed bioadhesive properties. India ink was used to stain the sites to confirm penetration.
The following data pertain to microneedle arrays of type E3, cast from a water solution (approximately 20.3% solids content) comprising BSA 5 wt %, PVA USP 20 wt %, hydroxypropyl β-cyclodextrin 15 wt %, trehalose 30 wt %, and maltitol 30 wt %. Data are also given for arrays of type E2 from Example 11 and for polysulfone (PSF) arrays, which do not dissolve.
In this table the TEWL data were obtained using anesthetized laboratory rats. The SPE (skin penetration efficiency) is measured by using India ink. The % Array needle dissolution value indicates the percentage of microneedles in the array that showed some dissolution, whereas the % Length indicates the percentage of the total length of the microneedles which dissolved. The dissolution was estimated by observing the needles under the microscope after use.
Sylgard 184 silicone elastomer from Dow Corning (Midland, Mich.) was given a surface treatment to improve wetting as follows. A quartz glass ring surrounded by a polyurethane ring were placed atop a 5 mm thick sheet of Sylgard 184. These formed a basin in which a monomer solution was placed. Methacrylic acid 1.58 g, water 14.42 g, benzyl alcohol 0.14 g, and NaIO4 0.0022 g were placed in the basin. A total dose of 9.98 J/cm2 of ultraviolet radiation was applied using an H type ultraviolet bulb three inches above the substrate. A conveyor was used to move the substrate past the ultraviolet bulb at 4 feet/minute for four passes. A UV Fusion Systems Model P300M was used for the ultraviolet exposure.
Wetting was measured by placing 10 μL drops of particular liquids on the treated and untreated silicone elastomer. The results are given in the following table (standard deviations in parentheses, N=3):
A similar experiment was carried out in which the Sylgard 184 was pretreated with a 1% solution of benzophenone in heptane and dried for 15 minutes at 32° C. A solution containing acrylic acid 5 g, benzyl alcohol 0.35 g, NaIO4 0.035 g, and water 45 g was applied to pretreated Sylgard 184. In both cases doses of approximately 9.6 J/cm2 of ultraviolet light were applied in a similar manner to the preceding experiment. The results are given in the following table:
A mixture of 10 g Sylgard base, 1 g Sylgard catalyst, and 0.55 g Q2-5211 was prepared, the base and catalyst being mixed first and the Q2-5211 being added subsequently. This mix was then spread over a PET liner at 0.60 mm thickness. The mix was cured for a period of hours at 165° F. The wet-out of the Q2-5211 sample was estimated by recording the spreading of a single drop of BSA (bovine serum albumin) casting solution through video. It was found that that there was a ˜260% increase in drop area compared to a control. The casting solution had the composition of Example 3, row A14.
In order to test the value of a “super wetting agent,” Dow Corning Q2-5211, with Sylgard 184 molds, the following tests were carried out. A mixture of 10 g Sylgard base, 1 g Sylgard catalyst, and 0.55 g Q2-5211 was prepared, the base and catalyst being mixed first and the Q2-5211 being added subsequently. This mix was then spread over a master microneedle array in order to prepare a mold. The mix on the master was placed under vacuum for 20 minutes and then cured for several hours at 155° F. Red food coloring was mixed with a BSA (bovine serum albumin) casting solution used in Example 3. Ten μL of this solution was pipetted onto the mold array. A half-inch-wide 30 mil thick piece of high impact polystyrene (HIPS) was used as a squeegee and the formulation was spread across the array several times.
The sample was placed on a small piece of Lexan® and vortexed for 5 seconds to homogenize the liquid layer and move entrapped air. The sample was placed in a pressure vessel and pressurized at 15 psi for 10 minutes. The sample was then removed and placed in a drying chamber for one hour. The sample was then removed and 75 μL of a second layer not containing BSA was spread over the back of the array using the squeegee. The sample was placed in the pressure vessel and pressurized at 15 psi for 2 minutes. The sample was removed and again placed in a drying chamber for one hour.
The array was removed from the mold by using a 17 mm button of 30 mil HIPS with double sided-adhesive on both sides of the button. One side of the button was adhered to a 17 mm diameter magnetic rod. The button was lowered on the array, gently compressed, then slowly removed while holding the silicone mold down. The button was then removed from the magnetic bar using a knife blade and the sample was adhered to a glass slide for better handling.
Microscopic examination of the array showed that the colored portion of the array was predominantly confined to the tips of the microprojections. This is attributed to superior wetting of the cast solutions on the mold on account of the inclusion of super wetting agent in the mold.
Microneedle arrays were made from polysulfone dissolved in dimethylformamide (DMF). Volumes of 150 and 200 μL were spread over a silicone mold to which a rim of PET was attached with PVP-PEG adhesive. The % solids in the casting solutions was 15 or 20%. The mold with casting solution was pressurized at 1 bar for 5 minutes. The whole was then placed in a 60° C. oven for periods ranging from 1 hour to overnight. The polysulfone was then demolded and the needles microscopically inspected. Air bubbles were seen in some cases, but other than the air bubbles, the microneedles appeared good.
Microneedle arrays were made from polystyrene dissolved in toluene. Volumes of 75 to 125 μL were spread over a silicone mold to which a rim of PET was attached with PVP-PEG adhesive. The % solids in the casting solutions was 15%. The mold with casting solution was pressurized at 1 bar for 5 minutes. The whole was then placed in a 60° C. oven for periods ranging from 2 to 3 h. The polystyrene was then demolded and the needles microscopically inspected. A small air bubble was seen in one case, but other than the air bubble, the microneedles appeared good.
Dry films of microneedle casting formulations were made using process conditions similar to those for casting microneedle arrays in order to evaluate the stability of hPTH (1-34 fragment) in the dried form. About 20 μL of liquid formulation is placed in an Eppendorf tube. The formulation is spread into a thin film in the inside wall of the tube, then dried at 32° C. for 30 min, and then further dried under vacuum at room temperature overnight. The dry films inside the Eppendorf tube were packaged in a polyfoil bag and stored at different temperatures for different durations. The purity of the hPTH(1-34) was analyzed by both reverse phase HPLC (rp-HPLC) and size exclusion HPLC (sec-HPLC). The details of the formulations are indicated in the table below.
The following table gives the details of formulations used to form dry films with hPTH as the drug.
Table A below illustrates the chemical purity as determined by rp-HPLC of the hPTH(1-34) in different formulations as a function of storage time at three different temperatures. Table B below illustrates the monomer content as determined by sec-HPLC of the hPTH(1-34) in different formulations as a function of storage time at three different temperatures. It appears that hPTH(1-34) is stable during storage for up to one month at even elevated temperature in all the formulations given in this example. (Formulation F3 was not sampled at the 1 week time point at room temperature or 40° C.)
This application claims priority to U.S. Provisional Application Ser. No. 60/923,861, filed Apr. 16, 2007, and U.S. Provisional Application Ser. No. 60/925,262, filed Apr. 18, 2007. These priority applications are incorporated by reference herein in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1554510 | Kirby | Sep 1925 | A |
| 1770632 | Smith | Jul 1930 | A |
| 2046240 | Bayley | Jun 1936 | A |
| 2434407 | George | Jan 1948 | A |
| 3675766 | Rosenthal | Jul 1972 | A |
| 3704194 | Harrier | Nov 1972 | A |
| 3814097 | Ganderton et al. | Jun 1974 | A |
| 3873255 | Kalwaites | Mar 1975 | A |
| 3918449 | Pistor | Nov 1975 | A |
| 3964482 | Gerstel et al. | Jun 1976 | A |
| 4055029 | Kalbow | Oct 1977 | A |
| 4117841 | Perrotta et al. | Oct 1978 | A |
| 4151240 | Lucas et al. | Apr 1979 | A |
| 4180232 | Hardigg | Dec 1979 | A |
| 4342314 | Radel et al. | Aug 1982 | A |
| 4381963 | Goldstein et al. | May 1983 | A |
| 4395215 | Bishop | Jul 1983 | A |
| 4402696 | Gulko | Sep 1983 | A |
| 4460368 | Allison et al. | Jul 1984 | A |
| 4460370 | Allison et al. | Jul 1984 | A |
| 4463045 | Ahr et al. | Jul 1984 | A |
| 4509908 | Mullane, Jr. | Apr 1985 | A |
| 4515168 | Chester et al. | May 1985 | A |
| 4556441 | Faasse, Jr. | Dec 1985 | A |
| 4585991 | Reid et al. | Apr 1986 | A |
| 4597961 | Etscorn | Jul 1986 | A |
| 4609518 | Curro et al. | Sep 1986 | A |
| 4630603 | Greenway | Dec 1986 | A |
| 4743249 | Loveland | May 1988 | A |
| 4784737 | Ray et al. | Nov 1988 | A |
| 4812305 | Vocal | Mar 1989 | A |
| 4837049 | Byers et al. | Jun 1989 | A |
| 4846821 | Lyons et al. | Jul 1989 | A |
| 4904475 | Gale et al. | Feb 1990 | A |
| 4966159 | Maganias | Oct 1990 | A |
| 5051259 | Olsen et al. | Sep 1991 | A |
| 5061258 | Martz | Oct 1991 | A |
| 5134079 | Cusak et al. | Jul 1992 | A |
| 5139029 | Fishman et al. | Aug 1992 | A |
| 5156591 | Gross et al. | Oct 1992 | A |
| 5158073 | Bukowski | Oct 1992 | A |
| 5160315 | Heinecke et al. | Nov 1992 | A |
| 5162043 | Lew et al. | Nov 1992 | A |
| 5190558 | Ito | Mar 1993 | A |
| 5198192 | Saito et al. | Mar 1993 | A |
| 5215088 | Normann et al. | Jun 1993 | A |
| 5244677 | Kreckel et al. | Sep 1993 | A |
| 5244711 | Drelich et al. | Sep 1993 | A |
| 5250023 | Lee et al. | Oct 1993 | A |
| 5250067 | Gelfer et al. | Oct 1993 | A |
| 5252279 | Gore et al. | Oct 1993 | A |
| 5256360 | Li | Oct 1993 | A |
| 5279544 | Gross et al. | Jan 1994 | A |
| 5308625 | Wong et al. | May 1994 | A |
| 5318557 | Gross | Jun 1994 | A |
| 5320600 | Lambert | Jun 1994 | A |
| 5330452 | Zook | Jul 1994 | A |
| 5362307 | Guy et al. | Nov 1994 | A |
| 5383512 | Jarvis | Jan 1995 | A |
| 5457041 | Ginaven et al. | Oct 1995 | A |
| 5462743 | Turner et al. | Oct 1995 | A |
| 5476443 | Cartmell et al. | Dec 1995 | A |
| 5487726 | Rabenau et al. | Jan 1996 | A |
| 5496304 | Chasan | Mar 1996 | A |
| 5498235 | Flower | Mar 1996 | A |
| 5503843 | Santus et al. | Apr 1996 | A |
| 5512219 | Rowland et al. | Apr 1996 | A |
| 5520629 | Heinecke et al. | May 1996 | A |
| 5527288 | Gross et al. | Jun 1996 | A |
| 5531675 | Yoo | Jul 1996 | A |
| 5531855 | Heinecke et al. | Jul 1996 | A |
| 5536263 | Rolf et al. | Jul 1996 | A |
| 5551953 | Lattin et al. | Sep 1996 | A |
| 5567376 | Turi et al. | Oct 1996 | A |
| 5591123 | Sibalis et al. | Jan 1997 | A |
| 5591139 | Lin et al. | Jan 1997 | A |
| 5611806 | Jang | Mar 1997 | A |
| 5645977 | Wu et al. | Jul 1997 | A |
| 5658515 | Lee et al. | Aug 1997 | A |
| 5662127 | De Vaughn | Sep 1997 | A |
| 5676850 | Reed et al. | Oct 1997 | A |
| 5681580 | Jang et al. | Oct 1997 | A |
| 5697901 | Ericksson | Dec 1997 | A |
| 5704520 | Gross | Jan 1998 | A |
| 5711761 | Untereker et al. | Jan 1998 | A |
| 5728089 | Lal et al. | Mar 1998 | A |
| 5730714 | Guy et al. | Mar 1998 | A |
| 5730721 | Hyatt et al. | Mar 1998 | A |
| 5735273 | Kurnik et al. | Apr 1998 | A |
| 5738642 | Heinecke et al. | Apr 1998 | A |
| 5756117 | D'Angelo et al. | May 1998 | A |
| 5771890 | Tamada | Jun 1998 | A |
| 5788983 | Chien et al. | Aug 1998 | A |
| 5800420 | Gross et al. | Sep 1998 | A |
| 5807375 | Gross et al. | Sep 1998 | A |
| 5814020 | Gross | Sep 1998 | A |
| 5820622 | Gross et al. | Oct 1998 | A |
| 5827183 | Kurnik et al. | Oct 1998 | A |
| 5843114 | Jang | Dec 1998 | A |
| 5848985 | Muroki | Dec 1998 | A |
| 5848990 | Cirelli et al. | Dec 1998 | A |
| 5848991 | Gross et al. | Dec 1998 | A |
| 5851549 | Svec | Dec 1998 | A |
| 5855801 | Lin et al. | Jan 1999 | A |
| 5873849 | Bernard | Feb 1999 | A |
| 5879326 | Godshall et al. | Mar 1999 | A |
| 5900252 | Calanchi et al. | May 1999 | A |
| 5932240 | D'Angelo et al. | Aug 1999 | A |
| 5938684 | Lynch et al. | Aug 1999 | A |
| 5948488 | Marecki et al. | Sep 1999 | A |
| 5962011 | Devillez et al. | Oct 1999 | A |
| 5964729 | Choi et al. | Oct 1999 | A |
| 5983136 | Kamen | Nov 1999 | A |
| 5987989 | Yamamoto et al. | Nov 1999 | A |
| 5997549 | Sauceda et al. | Dec 1999 | A |
| 5997986 | Turi et al. | Dec 1999 | A |
| 6014584 | Hofmann et al. | Jan 2000 | A |
| 6023629 | Tamada | Feb 2000 | A |
| 6024553 | Shimalla | Feb 2000 | A |
| 6036659 | Ray et al. | Mar 2000 | A |
| 6038465 | Melton, Jr. | Mar 2000 | A |
| 6038485 | Axelgaard | Mar 2000 | A |
| 6047208 | Flower | Apr 2000 | A |
| 6050988 | Zuck | Apr 2000 | A |
| 6055453 | Hofmann et al. | Apr 2000 | A |
| 6083196 | Trautman et al. | Jul 2000 | A |
| 6091975 | Daddona et al. | Jul 2000 | A |
| 6106751 | Talbot et al. | Aug 2000 | A |
| 6120792 | Juni | Sep 2000 | A |
| 6129696 | Sibalis | Oct 2000 | A |
| 6132449 | Lum et al. | Oct 2000 | A |
| 6132755 | Eicher et al. | Oct 2000 | A |
| 6135990 | Heller et al. | Oct 2000 | A |
| 6136008 | Becker et al. | Oct 2000 | A |
| 6156336 | Bracht | Dec 2000 | A |
| 6169224 | Heinecke et al. | Jan 2001 | B1 |
| 6181964 | Hofmann et al. | Jan 2001 | B1 |
| 6183434 | Eppstein | Feb 2001 | B1 |
| 6183770 | Muchin et al. | Feb 2001 | B1 |
| 6187210 | Lebouitz et al. | Feb 2001 | B1 |
| 6216034 | Hofmann et al. | Apr 2001 | B1 |
| 6219574 | Cormier et al. | Apr 2001 | B1 |
| 6230051 | Cormier et al. | May 2001 | B1 |
| 6241701 | Hofmann | Jun 2001 | B1 |
| 6256533 | Yuzhakov et al. | Jul 2001 | B1 |
| 6293925 | Safabash et al. | Sep 2001 | B1 |
| 6312612 | Sherman et al. | Nov 2001 | B1 |
| 6322808 | Trautman et al. | Nov 2001 | B1 |
| 6334856 | Allen et al. | Jan 2002 | B1 |
| 6355054 | Neuberger | Mar 2002 | B1 |
| 6375627 | Mauze et al. | Apr 2002 | B1 |
| 6375870 | Visovsky et al. | Apr 2002 | B1 |
| 6375978 | Kliener et al. | Apr 2002 | B1 |
| 6379324 | Garstein et al. | Apr 2002 | B1 |
| 6440096 | Lastovich et al. | Aug 2002 | B1 |
| 6451240 | Sherman et al. | Sep 2002 | B1 |
| 6471903 | Sherman et al. | Oct 2002 | B2 |
| 6476288 | Van Rijswijck et al. | Nov 2002 | B1 |
| 6494830 | Wessel | Dec 2002 | B1 |
| 6503231 | Prausnitz et al. | Jan 2003 | B1 |
| 6508947 | Gulvin et al. | Jan 2003 | B2 |
| 6511463 | Wood et al. | Jan 2003 | B1 |
| 6516223 | Hofmann | Feb 2003 | B2 |
| 6532386 | Sun et al. | Mar 2003 | B2 |
| 6533884 | Mallik | Mar 2003 | B1 |
| 6537242 | Palmer | Mar 2003 | B1 |
| 6537264 | Cormier et al. | Mar 2003 | B1 |
| 6558361 | Yeshurun | May 2003 | B1 |
| 6562014 | Lin et al. | May 2003 | B2 |
| 6565532 | Yuzhakov et al. | May 2003 | B1 |
| 6585742 | Stough | Jul 2003 | B2 |
| 6589202 | Powell | Jul 2003 | B1 |
| 6591124 | Sherman et al. | Jul 2003 | B2 |
| 6591133 | Joshi | Jul 2003 | B1 |
| 6603987 | Whiston | Aug 2003 | B2 |
| 6610463 | Ohkura et al. | Aug 2003 | B1 |
| 6611706 | Avrahami et al. | Aug 2003 | B2 |
| 6611707 | Prausnitz et al. | Aug 2003 | B1 |
| 6623457 | Rosenberg | Sep 2003 | B1 |
| 6629949 | Douglas | Oct 2003 | B1 |
| 6652478 | Gartstein et al. | Nov 2003 | B1 |
| 6656147 | Gertsek et al. | Dec 2003 | B1 |
| 6663820 | Arias et al. | Dec 2003 | B2 |
| 6685682 | Heinecke et al. | Feb 2004 | B1 |
| 6689103 | Palasis | Feb 2004 | B1 |
| 6691752 | DiSabatino | Feb 2004 | B2 |
| 6743211 | Prausnitz et al. | Jun 2004 | B1 |
| 6767341 | Cho | Jul 2004 | B2 |
| 6770480 | Canham | Aug 2004 | B1 |
| 6778853 | Heller et al. | Aug 2004 | B1 |
| 6780171 | Gabel et al. | Aug 2004 | B2 |
| 6808506 | Lastovich et al. | Oct 2004 | B2 |
| 6821281 | Sherman et al. | Nov 2004 | B2 |
| 6835184 | Sage et al. | Dec 2004 | B1 |
| 6855131 | Trautman et al. | Feb 2005 | B2 |
| 6881203 | Delmore et al. | Apr 2005 | B2 |
| 6931277 | Yuzhakov et al. | Aug 2005 | B1 |
| 6945952 | Kwon | Sep 2005 | B2 |
| 6960193 | Rosenberg | Nov 2005 | B2 |
| 6980855 | Cho et al. | Dec 2005 | B2 |
| 7011844 | Gale et al. | Mar 2006 | B2 |
| 7062317 | Avrahami et al. | Jun 2006 | B2 |
| 7087035 | Trautman et al. | Aug 2006 | B2 |
| 7097631 | Trautman et al. | Aug 2006 | B2 |
| 7108681 | Gartstein et al. | Sep 2006 | B2 |
| 7115108 | Wilkinson et al. | Oct 2006 | B2 |
| 7131960 | Trautman et al. | Nov 2006 | B2 |
| 7131987 | Sherman et al. | Nov 2006 | B2 |
| 7166086 | Haider et al. | Jan 2007 | B2 |
| 7184826 | Cormier et al. | Feb 2007 | B2 |
| 7186235 | Martin et al. | Mar 2007 | B2 |
| 7226439 | Prausnitz et al. | Jun 2007 | B2 |
| 7332339 | Canham | Feb 2008 | B2 |
| 7412284 | Hofmann | Aug 2008 | B2 |
| 7416541 | Yuzhakov et al. | Aug 2008 | B2 |
| 7419481 | Trautman et al. | Sep 2008 | B2 |
| 7572405 | Sherman et al. | Aug 2009 | B2 |
| 7578954 | Gartstein et al. | Aug 2009 | B2 |
| 7611481 | Cleary et al. | Nov 2009 | B2 |
| 7763203 | Arias et al. | Jul 2010 | B2 |
| 7785301 | Yuzhakov | Aug 2010 | B2 |
| 7798987 | Trautman et al. | Sep 2010 | B2 |
| 7828827 | Gartstein et al. | Nov 2010 | B2 |
| 7914480 | Cleary et al. | Mar 2011 | B2 |
| 8057842 | Choi et al. | Nov 2011 | B2 |
| 8216190 | Gartstein et al. | Jul 2012 | B2 |
| 8366677 | Kaspar et al. | Feb 2013 | B2 |
| 8702726 | Gartstein et al. | Apr 2014 | B2 |
| 8821446 | Trautman et al. | Sep 2014 | B2 |
| 20010023324 | Pronovost et al. | Sep 2001 | A1 |
| 20010023351 | Eilers et al. | Sep 2001 | A1 |
| 20020006355 | Whiston | Jan 2002 | A1 |
| 20020016562 | Cormier et al. | Feb 2002 | A1 |
| 20020020688 | Sherman et al. | Feb 2002 | A1 |
| 20020032415 | Trautman et al. | Mar 2002 | A1 |
| 20020042589 | Marsoner | Apr 2002 | A1 |
| 20020045859 | Gartstein et al. | Apr 2002 | A1 |
| 20020045907 | Sherman et al. | Apr 2002 | A1 |
| 20020082543 | Park et al. | Jun 2002 | A1 |
| 20020087182 | Trautman et al. | Jul 2002 | A1 |
| 20020091357 | Trautman et al. | Jul 2002 | A1 |
| 20020096488 | Gulvin et al. | Jul 2002 | A1 |
| 20020133129 | Arias et al. | Sep 2002 | A1 |
| 20020133137 | Hofmann | Sep 2002 | A1 |
| 20020138049 | Allen et al. | Sep 2002 | A1 |
| 20020169411 | Sherman et al. | Nov 2002 | A1 |
| 20020177839 | Cormier et al. | Nov 2002 | A1 |
| 20020177858 | Sherman et al. | Nov 2002 | A1 |
| 20020188245 | Martin et al. | Dec 2002 | A1 |
| 20020188310 | Seward et al. | Dec 2002 | A1 |
| 20020193729 | Cormier et al. | Dec 2002 | A1 |
| 20020193819 | Porter et al. | Dec 2002 | A1 |
| 20030093028 | Spiegel | May 2003 | A1 |
| 20030093089 | Greenberg | May 2003 | A1 |
| 20030135167 | Gonnelli | Jul 2003 | A1 |
| 20030166624 | Gale et al. | Sep 2003 | A1 |
| 20030187394 | Wilkinson et al. | Oct 2003 | A1 |
| 20030195474 | Down et al. | Oct 2003 | A1 |
| 20030199810 | Trautman et al. | Oct 2003 | A1 |
| 20030199812 | Rosenberg | Oct 2003 | A1 |
| 20030208138 | Olson | Nov 2003 | A1 |
| 20030208167 | Prausnitz et al. | Nov 2003 | A1 |
| 20030212397 | Avrahami et al. | Nov 2003 | A1 |
| 20030220610 | Lastovich et al. | Nov 2003 | A1 |
| 20030220656 | Gartstein et al. | Nov 2003 | A1 |
| 20040049150 | Dalton et al. | Mar 2004 | A1 |
| 20040062813 | Cormier et al. | Apr 2004 | A1 |
| 20040087893 | Kwon | May 2004 | A1 |
| 20040087992 | Gartstein et al. | May 2004 | A1 |
| 20040096455 | Maa et al. | May 2004 | A1 |
| 20040106904 | Gonnelli et al. | Jun 2004 | A1 |
| 20040143211 | Haider et al. | Jul 2004 | A1 |
| 20040146611 | Arias et al. | Jul 2004 | A1 |
| 20040164454 | Gartstein et al. | Aug 2004 | A1 |
| 20040181203 | Cormier et al. | Sep 2004 | A1 |
| 20040186419 | Cho et al. | Sep 2004 | A1 |
| 20040204669 | Hofmann | Oct 2004 | A1 |
| 20040220535 | Canham | Nov 2004 | A1 |
| 20040236271 | Theeuwes et al. | Nov 2004 | A1 |
| 20040265365 | Daddona et al. | Dec 2004 | A1 |
| 20050049549 | Wong et al. | Mar 2005 | A1 |
| 20050065463 | Tobinaga et al. | Mar 2005 | A1 |
| 20050089554 | Cormier et al. | Apr 2005 | A1 |
| 20050090803 | Sherman et al. | Apr 2005 | A1 |
| 20050096586 | Trautman et al. | May 2005 | A1 |
| 20050163827 | Zech et al. | Jul 2005 | A1 |
| 20050178760 | Chang et al. | Aug 2005 | A1 |
| 20050197308 | Dalton | Sep 2005 | A1 |
| 20050209565 | Yuzhakov et al. | Sep 2005 | A1 |
| 20050228340 | Cleary et al. | Oct 2005 | A1 |
| 20050261631 | Clarke et al. | Nov 2005 | A1 |
| 20060024358 | Santini et al. | Feb 2006 | A1 |
| 20060076718 | Sherman et al. | Apr 2006 | A1 |
| 20060095061 | Trautman et al. | May 2006 | A1 |
| 20060129174 | Gartstein et al. | Jun 2006 | A1 |
| 20060149297 | Sherman et al. | Jul 2006 | A1 |
| 20060253079 | McDonough et al. | Nov 2006 | A1 |
| 20070027427 | Trautman et al. | Feb 2007 | A1 |
| 20070191761 | Boone et al. | Aug 2007 | A1 |
| 20070255251 | Panchula et al. | Nov 2007 | A1 |
| 20080009811 | Cantor | Jan 2008 | A1 |
| 20080009825 | Ringsred et al. | Jan 2008 | A1 |
| 20080039805 | Frederickson et al. | Feb 2008 | A1 |
| 20080114298 | Cantor et al. | May 2008 | A1 |
| 20080125743 | Yuzhakov | May 2008 | A1 |
| 20080183144 | Trautman et al. | Jul 2008 | A1 |
| 20080195035 | Fredrickson et al. | Aug 2008 | A1 |
| 20080208146 | Brandwein et al. | Aug 2008 | A1 |
| 20080214987 | Xu | Sep 2008 | A1 |
| 20080269685 | Singh et al. | Oct 2008 | A1 |
| 20090043279 | Kaspar et al. | Feb 2009 | A1 |
| 20090155330 | Ghartey-Tagoe et al. | Jun 2009 | A1 |
| 20090216215 | Thalmann et al. | Aug 2009 | A1 |
| 20100028390 | Cleary et al. | Feb 2010 | A1 |
| 20100228203 | Quan et al. | Sep 2010 | A1 |
| 20100247698 | Zhang et al. | Sep 2010 | A1 |
| 20110006458 | Sagi et al. | Jan 2011 | A1 |
| 20110046638 | Gartstein et al. | Feb 2011 | A1 |
| 20110121486 | Oh et al. | May 2011 | A1 |
| 20110177139 | Jung et al. | Jul 2011 | A1 |
| 20110276027 | Trautman et al. | Nov 2011 | A1 |
| 20110276028 | Singh et al. | Nov 2011 | A1 |
| 20120150023 | Kaspar et al. | Jun 2012 | A1 |
| 20120184906 | McAllister | Jul 2012 | A1 |
| 20130131598 | Trautman et al. | May 2013 | A1 |
| 20130292868 | Singh et al. | Nov 2013 | A1 |
| 20130292886 | Sagi et al. | Nov 2013 | A1 |
| Number | Date | Country |
|---|---|---|
| 2376285 | Dec 2000 | CA |
| 2316534 | Mar 2001 | CA |
| 2422907 | Apr 2002 | CA |
| 02319591 | Nov 1974 | DE |
| 19518974 | Nov 1995 | DE |
| 19624578 | Jan 1998 | DE |
| 0156471 | Oct 1985 | EP |
| 0240593 | Oct 1987 | EP |
| 0301599 | Feb 1989 | EP |
| 0312662 | Apr 1989 | EP |
| 0400249 | Dec 1990 | EP |
| 0407063 | Jan 1991 | EP |
| 0796128 | Sep 1997 | EP |
| 1086718 | Mar 2001 | EP |
| 1086719 | Mar 2001 | EP |
| 1174078 | Jan 2002 | EP |
| 2283809 | Feb 2011 | EP |
| 2399624 | Dec 2011 | EP |
| 2535602 | May 1984 | FR |
| 0783479 | Sep 1957 | GB |
| 2221394 | Feb 1990 | GB |
| 2277202 | Oct 1994 | GB |
| 46-037758 | Dec 1971 | JP |
| 60-242042 | Dec 1985 | JP |
| 62-213763 | Sep 1987 | JP |
| 01-264839 | Oct 1989 | JP |
| 02-009755 | Mar 1990 | JP |
| 03-151951 | Jun 1991 | JP |
| 05-123326 | May 1993 | JP |
| 05-162076 | Jun 1993 | JP |
| 06-238644 | Aug 1994 | JP |
| 07-132119 | May 1995 | JP |
| 08-502215 | Mar 1996 | JP |
| 09-051878 | Feb 1997 | JP |
| 54-028369 | Mar 1997 | JP |
| 09-140687 | Jun 1997 | JP |
| 09-211022 | Aug 1997 | JP |
| 10-328168 | Dec 1998 | JP |
| 11-230707 | Aug 1999 | JP |
| 11-509123 | Aug 1999 | JP |
| 2000-146777 | May 2000 | JP |
| 2000-147229 | May 2000 | JP |
| 2000-164890 | Jun 2000 | JP |
| 2000-194142 | Jul 2000 | JP |
| 2000-232095 | Aug 2000 | JP |
| 2000-232971 | Aug 2000 | JP |
| 2000-322780 | Nov 2000 | JP |
| 2000-323461 | Nov 2000 | JP |
| 2001-004442 | Jan 2001 | JP |
| 2001-138300 | May 2001 | JP |
| 2001-149485 | Jun 2001 | JP |
| 2001-157715 | Jun 2001 | JP |
| 2001-341314 | Dec 2001 | JP |
| 2002-079499 | Mar 2002 | JP |
| 2002-151395 | May 2002 | JP |
| 2002-239014 | Aug 2002 | JP |
| 2002-301698 | Oct 2002 | JP |
| 2003-039399 | Feb 2003 | JP |
| 2003-048160 | Feb 2003 | JP |
| 2003-534881 | Nov 2003 | JP |
| 2004-065775 | Mar 2004 | JP |
| 2007-190112 | Jan 2006 | JP |
| 2006-341089 | Dec 2006 | JP |
| 2007-130030 | May 2007 | JP |
| 2008-006178 | Jan 2008 | JP |
| 2008-194288 | Aug 2008 | JP |
| 2010-233674 | Oct 2010 | JP |
| 20100064669 | Jun 2010 | KR |
| 1641346 | Apr 1991 | SU |
| 1667864 | Aug 1991 | SU |
| WO 9315701 | Aug 1993 | WO |
| WO 9317754 | Sep 1993 | WO |
| WO 9423777 | Oct 1994 | WO |
| WO 9522612 | Aug 1995 | WO |
| WO 9533612 | Dec 1995 | WO |
| WO 9600109 | Jan 1996 | WO |
| WO 9617648 | Jun 1996 | WO |
| WO 9637155 | Nov 1996 | WO |
| WO 9637256 | Nov 1996 | WO |
| WO 9703718 | Feb 1997 | WO |
| WO 9713544 | Apr 1997 | WO |
| WO 9748440 | Dec 1997 | WO |
| WO 9748441 | Dec 1997 | WO |
| WO 9748442 | Dec 1997 | WO |
| WO 9800193 | Jan 1998 | WO |
| WO 9828307 | Jul 1998 | WO |
| WO 9900155 | Jan 1999 | WO |
| WO 9929298 | Jun 1999 | WO |
| WO 9929364 | Jun 1999 | WO |
| WO 9929365 | Jun 1999 | WO |
| WO 9961888 | Dec 1999 | WO |
| WO 9964580 | Dec 1999 | WO |
| WO 0005166 | Feb 2000 | WO |
| WO 0035530 | Jun 2000 | WO |
| WO 0070406 | Nov 2000 | WO |
| WO 0074763 | Dec 2000 | WO |
| WO 0074764 | Dec 2000 | WO |
| WO 0074765 | Dec 2000 | WO |
| WO 0074766 | Dec 2000 | WO |
| WO 0077571 | Dec 2000 | WO |
| WO 0108242 | Feb 2001 | WO |
| WO 0136037 | May 2001 | WO |
| WO 0136321 | May 2001 | WO |
| WO 0149362 | Jul 2001 | WO |
| WO 0202180 | Jan 2002 | WO |
| WO 0207543 | Jan 2002 | WO |
| WO 0207813 | Jan 2002 | WO |
| WO 0217985 | Mar 2002 | WO |
| WO 0230301 | Apr 2002 | WO |
| WO 0232331 | Apr 2002 | WO |
| WO 0232480 | Apr 2002 | WO |
| WO 02062202 | Aug 2002 | WO |
| WO 02064193 | Aug 2002 | WO |
| WO 02072189 | Sep 2002 | WO |
| WO 02091922 | Nov 2002 | WO |
| WO 02100474 | Dec 2002 | WO |
| WO 03024290 | Mar 2003 | WO |
| WO 03024518 | Mar 2003 | WO |
| WO 03026733 | Apr 2003 | WO |
| WO 04000389 | Dec 2003 | WO |
| WO 2004024224 | Mar 2004 | WO |
| WO 2004076339 | Sep 2004 | WO |
| WO 2004110717 | Dec 2004 | WO |
| WO 2005082596 | Sep 2005 | WO |
| WO 2005089857 | Sep 2005 | WO |
| WO 2005094526 | Oct 2005 | WO |
| WO 2006020842 | Feb 2006 | WO |
| WO 2006055795 | May 2006 | WO |
| WO 2006101459 | Sep 2006 | WO |
| WO 2007002521 | Jan 2007 | WO |
| WO 2007002523 | Jan 2007 | WO |
| WO 2007030477 | Mar 2007 | WO |
| WO 2007075806 | Jul 2007 | WO |
| WO 2007081430 | Jul 2007 | WO |
| WO 2007124411 | Nov 2007 | WO |
| WO 2008011625 | Jan 2008 | WO |
| WO 2008024141 | Feb 2008 | WO |
| WO 2008091602 | Jul 2008 | WO |
| WO 2008130587 | Oct 2008 | WO |
| WO 2008139648 | Nov 2008 | WO |
| WO 2009039013 | Mar 2009 | WO |
| WO 2009048607 | Apr 2009 | WO |
| WO 2009054988 | Apr 2009 | WO |
| WO 2009142741 | Nov 2009 | WO |
| WO 2010040271 | Apr 2010 | WO |
| WO 2010124255 | Oct 2010 | WO |
| WO 2011121023 | Oct 2011 | WO |
| WO 2011140240 | Oct 2011 | WO |
| WO 2011140274 | Oct 2011 | WO |
| WO 2012054582 | Apr 2012 | WO |
| WO 2012122163 | Sep 2012 | WO |
| Entry |
|---|
| Chun, et al., “An array of hollow microcapillaries for the controlled injection of genetic materials into animal/plant cells,” IEEE Workshop on Micro Electro Mechanical Systems, pp. 406-411, (1999). |
| Henry, et al., “Micromachined microneedles for transdermal delivery of drugs”, IEEE Workshop on Micro Electro Mechanical Systems, New York, NY, pp. 494-498, (1998). |
| Henry, et al., “Microfabricated microneedles: A novel approach to transdermal drug delivery”, J. Pharmaceutical Science, vol. 87, No. 8, pp. 922-925, (1998). |
| “Heparin Pregnancy and Breast Feeding Warnings”, Drugs.com, Accessed Oct. 8, 2009, <http://www.drugs.com/pregnancy/heparin.html>. |
| International Search Report from PCT/US2000/015612 mailed on Sep. 7, 2000. |
| International Search Report from PCT/US2000/015613 mailed on Sep. 6, 2000. |
| International Search Report from PCT/US2000/015614 mailed on Sep. 6, 2000. |
| International Search Report from PCT/US2001/031977 mailed on Apr. 29, 2002. |
| International Search Report from PCT/US2001/031978 mailed on Apr. 29, 2002. |
| International Search Report from PCT/US2002/014624 mailed on Sep. 3, 2002. |
| International Search Report from PCT/US2002/029228 mailed on Apr. 23, 2003. |
| International Search Report from PCT/US2002/029245 mailed on Dec. 27, 2002. |
| International Search Report from PCT/US2004/005382 mailed on Nov. 25, 2004. |
| International Search Report from PCT/US2004/017255 mailed on May 24, 2005. |
| International Search Report from PCT/US2005/009854 mailed on Jul. 3, 2008. |
| International Search Report from PCT/US2008/000824 mailed on Jul. 18, 2008. |
| International Search Report from PCT/US2008/004943 mailed on Jun. 9, 2009. |
| Matriano, et al., “Macroflux(R) microprojection array patch technology: A new and efficient approach for intracutaneous immunization”, Pharm. Res., vol. 19, No. 1, pp. 63-70, (2002). |
| McAllister, et al., “Micromachined microneedles for transdermal drug delivery”, Am. Inst. Chem. Eng., 1998 Annual Meeting, Miami Beach, FL, Nov. 15-20, Drug Delivery II, pp. 1-4. |
| Mikszta, et al., “Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery”, Nat. Med., vol. 8, No. 4, pp. 415-419, (2002). |
| Mikszta, et al., “Protective immunization against inhalation anthrax: A comparison of minimally invasive delivery platforms”, J. Inf. Dis., vol. 191, No. 2, pp. 278-288, (2005). |
| Papautsky, et al., “Micromachined Pipette Arrays,” MPA, Proceedings—19th international Conference—IEEE/EMBS, Chicago IL, USA, pp. 2281-2284 (1997). |
| Park, et al. “Polymer Microneedles for Controlled-Release Drug Delivery,” Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NE, vol. 23, No. 5, pp. 1008-1019 (2006). |
| Prausnitz, et al., “Transdermal transport efficiency during skin electroporation and iontophoresis”, J. Contr. Release, vol. 38, pp. 205-217, (1996). |
| Prausnitz, “Transdermal delivery of macromolecules: Recent advances by modification of skin's barrier properties”, ACS Symposium Series No. 675, Therapeutic Protein and Peptide Formulation and Delivery, American Chemical Society, Washington DC, Chapter 8, pp. 124-153, (1997). |
| Rydberg, et al., “Low-molecular-weight heparin preventing and treating DVT”, Am. Fam. Physician, vol. 9, No. 6, pp. 1607-1612, (1999). |
| Sivamani, et al., “Microneedles and transdermal applications”, Exp. Opin. Drug Del., vol. 4, No. 1, pp. 19-25, (2007). |
| Wouters, et al., “Microelectrochemical systems for drug delivery”, Electrochimica Acta., vol. 42, pp. 3385-3390, (1997). |
| Xia, et al., “Soft Lithography”, Angew. Chem. Int. Ed., vol. 37, pp. 551-575, (1998). |
| Xia, et al., “Soft Lithography”, Annu. Rev. Mater. Sci., vol. 28, pp. 153-184 (1998). |
| “Extend”, Merriam-Webster Online Dictionary, Online article accessed on Sep. 7, 2010 from http://www.merriam-webster.com/dictionary/extend, Merriam-Webster Incorporated, 6 pgs., (2010). |
| “Extend”, Macmillian Online Dictionnary, Online article accessed Sep. 7, 2010 from http://www.macmillandictionary.com/dictionary/american/extend, Macmillan Publishers Limited, 5 pgs., (2010). |
| International Search Report from PCT/US2008/011635 mailed on Dec. 19, 2008. |
| International Search Report from PCT/US2010/032299 mailed on Dec. 10, 2010, application now published as WO 2010/124255 on Oct. 28, 2010. |
| International Search Report from International Patent Application No. PCT/US2013/077281 mailed Mar. 4, 2013. |
| International Search Report from International Patent Application No. PCT/US2014/021841 mailed Aug. 11, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/022087 mailed May 23, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/022859 mailed May 26, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/026179 mailed Jul. 18, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/029601 mailed Jul. 1, 2014. |
| Park et al., “Biodegradable polymer microneedles: Fabrication, mechanics, and transdermal drug delivery”, J. Contr. Rel., vol. 104, pp. 51-66 (2005). |
| Number | Date | Country | |
|---|---|---|---|
| 20080269685 A1 | Oct 2008 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60923861 | Apr 2007 | US | |
| 60925262 | Apr 2007 | US |
